Study Reveals Treatment Strategy for Triple-Negative Breast Cancer
Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
Mateusz Opyrchal, MD, PhD, of Roswell Park Cancer Institute in Buffalo, talks about a novel interaction between AURKA and the MAPK pathway in wild-type BRAF breast cancer cells and the cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen-positive and triple-negative breast cancer cells.
Dr. Opyrchal gave a presentation at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Eva Ciruelos;Ji-Yeon Kim;Elena López-Miranda;Elia Seguí;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Alessandro Di Sanzo;Paula Muñoz Romero;Bartomeu Piza Vallespir;Manuel Dominguez;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 24th 2025Article
